- 5 May 2011
- journal article
- Published by Wiley in Pediatric Blood & Cancer
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Cellular Strategies for Regulating DNA Supercoiling: A Single-Molecule PerspectiveCell, 2010
- Initial testing of topotecan by the pediatric preclinical testing programPediatric Blood & Cancer, 2009
- Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing programPediatric Blood & Cancer, 2007
- Phase II Trial of Irinotecan in Children With Relapsed or Refractory Rhabdomyosarcoma: A Joint Study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study GroupJournal of Clinical Oncology, 2007
- Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid TumorsJournal of Clinical Oncology, 2006
- Oncogenic pathway signatures in human cancers as a guide to targeted therapiesNature, 2005
- A Predictive Model of Human Myelotoxicity Using Five Camptothecin Derivatives and the In vitro Colony-Forming Unit Granulocyte/Macrophage AssayClinical Cancer Research, 2004
- Integrating pharmacology and in vivo cancer models in preclinical and clinical drug developmentEuropean Journal of Cancer, 2004
- Exploration, normalization, and summaries of high density oligonucleotide array probe level dataBiostatistics, 2003
- Phase I Trial and Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Topotecan Using a Five-Day Course in Children with Refractory Solid TumorsJournal of Pediatric Hematology/Oncology, 1996